ArticleInternational journal of medical sciences2026
The efferocytosis-related genes of SLC26A6, TYRO3, and PDK4 have been identified as predictors of prognosis in hepatocellular carcinoma and are associated with the immune status.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efferocytosis plays a critical role in clearing apoptotic tumor cells and suppressing inflammation in hepatocellular carcinoma (HCC). This study aimed to identify efferocytosis-related genes (ERGs) with prognostic value and develop a predictive model for HCC outcomes. Methods: Using public HCC transcriptomic and clinical data, we identified 13 differentially expressed ERGs (DE-ERGs) from 3,866 DEGs and 74 known ERGs. Cox regression analysis selected SLC26A6, TYRO3, and PDK4 as key prognostic genes for risk model construction. The model, combined with pathologic T stage in a nomogram, showed high predictive accuracy for patient survival. Results: Totally 13 DE-ERGs were gained by overlapping 3,866 DEGs and 74 ERGs, and SLC26A6, TYRO3, and PDK4 were identified as prognosis genes for constructing a risk model with highly proficient in assessing the risk of HCC patients. Then, both risk score and pathologic T stage were recognized as independent factors prognosticating the outcome of HCC patients. Afterwards, we constructed a nomogram utilizing risk score and pathologic T stage to achieve high accuracy in predicting the survival outcomes of HCC patients. Groups at low risk demonstrated enrichment in pathways related to biometabolism and immune response, such as "fatty acid metabolism" and "complement and coagulation cascades". Additionally, the strongest positive and negative correlation were observed from activated CD4 Conclusion: We identified three prognostic genes associated with efferocytosis in HCC and integrated them into a risk prognostic model. These genes not only serve as signatures for predicting HCC prognosis but also offer insights into the treatment of HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.